Effects of intragestational ghrelin misbalances on maternal immune parameters and fertility.

PAIRA DA; TORRES PJ; DÍAZ LUJÁN C; MOTRICH R; LUQUE EM; SALAZAR FC; MARTINI AC

Buenos Aires

Congreso; Reunión Conjunta de Sociedades de Biociencias.; 2017

SAFIS-SAIC-etc

Maternal and fetal ghrelin (Ghr) concentrations normally increase during pregnancy suggesting that this hormone exerts important roles on early gestational events. Moreover, some available evidence indicates that Ghr has immunomodulatory properties. Herein, we aimed to evaluate the effects of Ghr and its pharmacological blockade (antagonist treatment) on implantation events using an already validated mouse model of Ghr misbalance during pregnancy.Albino Swiss (N:NIH) mice dams were s.c. injected with Ghr (4 nmol/animal/day), an antagonist [Ant: (D-Lys3)GHRP-6; 6 nmol/animal/day] or vehicle (C: saline solution) from day 3 to 8 of gestation. Dams were euthanized at day 8, uteri exposed and analyzed macro and microscopically. The percentages of normal or atrophied fetuses and the number of implantation or resorbtion sites were recorded. In addition, the expression levels of VEGF, MMP9, GM-CSF, IL-10, IL-17 and IL-6 in uterine tissue was analyzed by qPCR. Plasma progesterone (P4) concentrations were quantified by ELISA. Results was analyzed by ANOVA.The blockade of Ghrelin (Ant) increased the number of resorbtion sites (C=0.5±0.5, Ghr=1.2±0.4, Ant=3.7±0.5; p0.05).Up to date, our results suggest that Ghr misbalance affects fertility by impairing embryo development not related to immune cytokine alterations at the maternal interface or by altering systemic P4 levels. Additional experiments are being carried out in order to unveil the putative underlying mechanisms of these effects.